News related to Clobex (Clobetasol Topical) and/or conditions it is approved for
International Psoriasis Council Hosts Second Educational Symposium To Increase Global Knowledge Of Psoriasis
Source: Dermatology News From Medical News Today [2009.11.18]
Beginning Thursday, Nov. 19, 2009, the International Psoriasis Council (IPC) will host its second symposium at Baylor University Medical Center in Dallas. The two-day conference brings together dermatologists from Asia, Eastern Europe and Spain to elevate the global understanding of psoriasis and its treatment. Sessions will be facilitated by leading dermatologists and nurses dedicated to psoriasis management and research.
Psoriatic arthritis common in people with psoriasis (Reuters)
Source: Y! Health Arthritis News [2009.11.05]
Reuters - As many as 14 percent of people with psoriasis may also have psoriatic arthritis, research shows.
EADV: Psoriasis Comorbidities May Cut Longevity (CME/CE)
Source: MedPage Today Dermatology [2009.10.14]
BERLIN (MedPage Today) -- Psoriasis patients have a substantial comorbidity burden that can reduce life expectancy by 10 years or more, according to data presented here.
EADV: Benefit of Methrotrexate in Psoriasis Will Show Up Early (CME/CE)
Source: MedPage Today Dermatology [2009.10.14]
BERLIN (MedPage Today) -- A suboptimal response to methotrexate at 12 weeks identified psoriasis patients who were unlikely to benefit from continued therapy at higher doses, a retrospective analysis of clinical-trial data showed.
EADV: Anti-TNF Exposure Does Not Rule out TNF Inhibitor for Psoriasis (CME/CE)
Source: MedPage Today Dermatology [2009.10.13]
BERLIN (MedPage Today) -- Prior exposure to anti-tumor necrosis factor (TNF) therapy does not rule out potential benefits from additional anti-TNF therapy for patients with psoriasis, according to data presented here.
EADV: Cytokine Inhibitor Has High Psoriasis Response (CME/CE)
Source: MedPage Today Dermatology [2009.10.12]
BERLIN (MedPage Today) -- More than 80% of patients with moderate to severe psoriasis had major responses to an investigational interleukin inhibitor, investigators reported here.
EADV: Interleukin Inhibitor Works Across Psoriasis Subgroups (CME/CE)
Source: MedPage Today Dermatology [2009.10.12]
BERLIN (MedPage Today) -- A newly approved cytokine inhibitor demonstrated consistent activity across a range of psoriasis patient subgroups and showed no loss of efficacy in heavier patients with appropriate dosing, according to data reported here.
EADV: Systemic Psoriasis Therapy Often Delayed (CME/CE)
Source: MedPage Today Dermatology [2009.10.12]
BERLIN (MedPage Today) -- Patients with psoriasis resistant to topical therapy frequently wait a year or longer to receive systemic therapy, investigators reported here.
EADV: High Rate of Metabolic Syndrome in Psoriasis Patients (CME/CE)
Source: MedPage Today Dermatology [2009.10.09]
BERLIN (MedPage Today) -- More than half of patients with psoriasis met diagnostic criteria for metabolic syndrome and had a high prevalence of associated risk factors, according to data from a small cohort study.
EADV: TNF Inhibitor Active in Palmoplantar Psoriasis (CME/CE)
Source: MedPage Today Dermatology [2009.10.09]
BERLIN (MedPage Today) -- Patients with palmoplantar psoriasis had at least 50% improvement after 14 weeks when treated with a tumor necrosis factor (TNF) inhibitor, according to results of a small clinical trial reported here.
EADV: Scalp, Nail Psoriasis Improve with TNF Inhibitor (CME/CE)
Source: MedPage Today Dermatology [2009.10.09]
BERLIN (MedPage Today) -- Treatment with a tumor necrosis factor (TNF) inhibitor significantly improved scalp and nail psoriasis as well as skin lesions, according to a retrospective analysis of a randomized clinical trial.
Stelara Approved for Psoriasis
Source: MedicineNet Psoriasis Specialty [2009.09.28]
Title: Stelara Approved for Psoriasis
Category: Health News
Created: 9/25/2009 4:10:00 PM
Last Editorial Review: 9/28/2009
Brain Can Cope With Emotions of Psoriasis
Source: MedicineNet Psoriasis Specialty [2009.08.28]
Title: Brain Can Cope With Emotions of Psoriasis
Category: Health News
Created: 8/28/2009
Last Editorial Review: 8/28/2009
Psoriasis May Raise Cardiovascular Risks
Source: MedicineNet Psoriasis Specialty [2009.06.16]
Title: Psoriasis May Raise Cardiovascular Risks
Category: Health News
Created: 6/16/2009
Last Editorial Review: 6/16/2009
Psoriasis Patients Happy With Home-Based Treatment
Source: MedicineNet Psoriasis Specialty [2009.05.08]
Title: Psoriasis Patients Happy With Home-Based Treatment
Category: Health News
Created: 5/8/2009 10:31:00 AM
Last Editorial Review: 5/8/2009
Psoriasis
Source: MedicineNet Actinic Keratosis Specialty [2009.05.01]
Title: Psoriasis
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 5/1/2009
Psoriasis Linked to Hypertension, Diabetes
Source: MedicineNet Psoriasis Specialty [2009.04.21]
Title: Psoriasis Linked to Hypertension, Diabetes
Category: Health News
Created: 4/21/2009
Last Editorial Review: 4/21/2009
Remicade Phase 3 data show long-term psoriasis response
Source: The Doctors Lounge - Dermatology
Findings from two Phase 3 studies show high-level, sustained response with maintenance therapy.
Cells That Control Inflammation In Chronic Disease
Source: Respiratory / Asthma News From Medical News Today [2009.11.19]
A new type of immune cell that can be out of control in certain chronic inflammatory diseases, worsening the symptoms of conditions like psoriasis and asthma, is described for the first time this week in the Journal of Clinical Investigation.
Tapping Into Curry's Health Benefits (HealthDay)
Source: Y! Health News Search RSS Feed [2009.11.13]
HealthDay - FRIDAY, Nov. 13 (HealthDay News) -- Tiny capsules could increase
the body's absorption of the yellow curry ingredient curcumin, which is
being tested in clinical trials for the treatment of colon cancer,
psoriasis and Alzheimer's disease.
EADV: Agent Clears Lesions, Lessens Psoriatic Arthritis (CME/CE)
Source: MedPage Today Dermatology [2009.10.14]
BERLIN (MedPage Today) -- In patients with psoriasis and concomitant psoriatic arthritis, treatment with etanercept (Enbrel) improved skin lesions, enthesitis, and dactylitis in a majority of patients, data from a randomized clinical trial showed.
|
